Tuskegee and the Nuremberg Code
One of the most consequential and troubling chapters in the history of clinical research began in 1932, when the United States Public Health Service launched a study in Macon County, Alabama, that tracked the natural progression of untreated syphilis in roughly 600 Black men, about two-thirds of whom had the disease. Researchers told participants they were being treated for “bad blood” without disclosing the actual diagnosis, and — most damningly — continued withholding treatment even after penicillin became the widely available, standard, curative treatment for syphilis by 1947, allowing men to suffer entirely preventable complications and, in some cases, die for decades after an effective cure existed. The study continued for forty years, only ending in 1972 after Public Health Service employee Peter Buxtun, who had raised internal objections years earlier without success, disclosed the study to a journalist, triggering national outrage and congressional hearings.
The Tuskegee study wasn’t the first instance of research ethics violations to shape modern clinical trial standards; it followed, by decades, an even more extreme set of atrocities. After World War II, the Nuremberg trials of Nazi physicians who had conducted brutal, often fatal human experimentation on concentration camp prisoners produced, in 1947, a set of ten ethical principles known as the Nuremberg Code — the first formal international standard for research involving human subjects, with voluntary, informed consent listed as its foundational requirement. Despite the code’s existence, it carried no direct legal enforcement mechanism in the United States, which is part of why a study as ethically indefensible as Tuskegee was able to continue for a further quarter-century after the code was written.
From the Declaration of Helsinki to Modern Trial Design
The World Medical Association adopted the Declaration of Helsinki in 1964, building directly on the Nuremberg Code but writing it specifically as guidance for physicians conducting research, and introducing the idea that an independent committee — not just the researcher’s own judgment — should review a study’s ethics before it began. The fallout from Tuskegee’s exposure in 1972 drove the United States to formalize similar protections into federal law: the National Research Act of 1974 established Institutional Review Boards, independent committees now required to approve and monitor human research at essentially every American research institution, and the resulting Belmont Report of 1979 distilled research ethics into three core principles still cited today — respect for persons, beneficence, and justice.
Parallel to these ethical reforms, the scientific methodology of clinical trials was also being formalized. British statistician Austin Bradford Hill designed what is widely considered the first modern randomized controlled trial in 1948, testing the antibiotic streptomycin against tuberculosis by randomly assigning patients to treatment or control groups — a methodological innovation that, combined with the double-blind, placebo-controlled design that became standard in the following decades, established the basic architecture nearly every clinical trial still follows today. Modern trial design and modern research ethics developed along separate but connected historical tracks — one asking whether a treatment works, the other asking whether testing it was done right — and both remain inseparable from how any new drug reaches approval today.
Source: National Institutes of Health (NIH) and Encyclopaedia Britannica.